| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in financing activities | -22,700 | -6,800 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 100 | 300 |
| Net change in cash, cash equivalents and restricted cash | 143,600 | 165,400 |
| Cash and cash equivalents at beginning of period | 105,600 | - |
| Cash and cash equivalents at end of period | 249,200 | - |
Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS)